CYP4B1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1165314	0.47	3/20
SCHEMBL971260	0.42	3/20
SCHEMBL2091704	0.41	3/20
SCHEMBL971261	0.40	3/20
Trifluoroacetic Acid (SCHEMBL2566375)	0.90	2/20
Trifluoroacetic Acid (SCHEMBL2592428)	0.90	2/20
Trifluoroacetic Acid (SCHEMBL2570005)	0.89	2/20
SCHEMBL2584612	0.79	2/20
SCHEMBL2407878	0.74	2/20
SCHEMBL196765	0.73	2/20
SCHEMBL2580241	0.72	2/20
Trifluoroacetic Acid (SCHEMBL2592437)	0.70	2/20
SCHEMBL2582318	0.68	2/20
SCHEMBL1180429	0.67	2/20
SCHEMBL1181635	0.67	2/20
SCHEMBL1181204	0.65	2/20
SCHEMBL2565135	0.65	2/20
SCHEMBL2087935	0.65	2/20
SCHEMBL2571823	0.63	2/20
SCHEMBL2570089	0.63	2/20

Clinical trials — most relevant to CYP4B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer	PHASE2	COMPLETED
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI	PHASE2	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)	PHASE2	COMPLETED
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	UNKNOWN
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies	PHASE1	COMPLETED
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab	PHASE1	COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction	nan	COMPLETED
Pharmacogenetic Dosage Algorithm for Acenocoumarol	nan	COMPLETED
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours	nan	COMPLETED
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain	nan	UNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients	nan	COMPLETED
Cyclophosphamide in Lupus Nephritis	nan	UNKNOWN
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP4B1 binder may also engage these)

Protein	Name	Similarity
P15128	—	1.000	P15128 →
Q64462	—	0.999	Q64462 →
O88833	—	0.992	O88833 →
P20816	—	0.992	P20816 →
P20817	—	0.992	P20817 →
P15129	—	0.992	P15129 →
A2A974	—	0.990	A2A974 →
P24464	—	0.989	P24464 →
O35728	—	0.987	O35728 →
CYP4X1	Cytochrome P450 4X1	0.987	landscape →
Q8SPK1	—	0.987	Q8SPK1 →
P08516	—	0.986	P08516 →
CYP4F2	Cytochrome P450 4F2	0.984	landscape →
CYP4F3	Cytochrome P450 4F3	0.984	landscape →
Q9GJX5	—	0.983	Q9GJX5 →
CYP4Z1	Cytochrome P450 4Z1	0.983	landscape →
Q6A152	—	0.983	Q6A152 →
Q8SPK0	—	0.982	Q8SPK0 →
Q91WL5	—	0.981	Q91WL5 →
Q0IIF9	—	0.979	Q0IIF9 →
P14581	—	0.979	P14581 →
CYP4F11	Cytochrome P450 4F11	0.979	landscape →
Q9EP75	—	0.978	Q9EP75 →
Q8K4D6	—	0.977	Q8K4D6 →
Q4V8D1	—	0.977	Q4V8D1 →
P51869	—	0.976	P51869 →
P14579	—	0.975	P14579 →
Q3MID2	—	0.974	Q3MID2 →
Q9CX98	—	0.973	Q9CX98 →
CYP2U1	Cytochrome P450 2U1 (Long-chain fatty acid om	0.972	landscape →